Intravesical interferon alfa in the treatment of superficial bladder cancer.
Williams
R D
RD
Department of Urology, University of Iowa Hospitals and Clinics, Iowa City 52242.
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D011994:Recombinant Proteins; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins